[Form 4] CME GROUP INC. Insider Trading Activity

Rhea-AI Filing Summary

CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.

On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sammann Derek

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr MD Gl Hd Commodities Mkts

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	11/06/2025		J	V	2,300	D	$0	8,683(1)	D
Common Stock Class A	11/06/2025		J	V	2,300	A	$0	16,914(1)	I	by Trust
Common Stock Class A	11/20/2025		S		5,886	D	$275.65	11,028	I	by Trust
Common Stock Class A	11/20/2025		S		1,314	D	$275.74	7,022	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Ownership has been updated to reflect the transfer of CME Group Class A common stock on November 6, 2025 to reporting person's revocable living trust.

Remarks:

	By: Margaret Austin Wright For: Derek Louis Sammann	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CME (CME) report for Derek Louis Sammann?

The filing shows that Derek Louis Sammann reported a transfer of 2,300 CME Class A shares on November 6, 2025 and sales totaling 5,886 shares by his trust and 1,314 shares by his spouse on November 20, 2025.

How did Derek Sammann’s direct CME share ownership change?

After the 2,300-share transfer on November 6, 2025, Derek Sammann’s direct holdings in CME Class A common stock were reported as 8,683 shares.

How many CME shares are held in Derek Sammann’s revocable living trust?

Following the reported transactions, the revocable living trust held 11,028 CME Class A shares after selling 5,886 shares at $275.65 on November 20, 2025.

What CME share transactions were reported for Derek Sammann’s spouse?

On November 20, 2025, Derek Sammann’s spouse sold 1,314 CME Class A shares at $275.74 per share, leaving 7,022 shares held by the spouse.

What was the purpose of the November 6, 2025 CME stock transfer?

The explanation states that ownership was updated to reflect the transfer of CME Group Class A common stock on November 6, 2025 to Derek Sammann’s revocable living trust.

What prices were received for the CME shares sold on November 20, 2025?

The trust’s sale of 5,886 shares was at $275.65 per share, and the spouse’s sale of 1,314 shares was at $275.74 per share.